Triple-negative breast cancer (TNBC), also known as estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, accounts for 15~20% of newly diagnosed breast cancers [1, 2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.